Veterinary Blog for Education, Careers, and Real Vet Life

Welcome to the Vet Candy Blog—your go-to destination for veterinary education, career growth, and real-life insights from the world of animal health.

From free RACE-approved CE courses and clinical updates to NAVLE prep and career advice, our content is designed for veterinarians, vet techs, and students who want to stay informed, inspired, and ahead in their careers.

Latest Veterinary News & Clinical Insights

Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
My Vet Candy My Vet Candy

Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats

PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.

Read More
Unraveling the Genetics of Feline Hypertrophic Cardiomyopathy: Insights from a Multiomics Study of 138 Cats
Jill Lopez Jill Lopez

Unraveling the Genetics of Feline Hypertrophic Cardiomyopathy: Insights from a Multiomics Study of 138 Cats

This article reviews a groundbreaking multiomics study investigating the genetics of feline hypertrophic cardiomyopathy (HCM) in 138 domestic cats. It discusses how whole genome sequencing and RNA transcriptomics revealed rare genetic variants and distinct molecular signatures linked to HCM. The findings highlight the complexity of feline HCM genetics and point to future opportunities for biomarker discovery and targeted therapies. Keywords include feline HCM genetics, RNA sequencing in cats, inherited cat heart disease, and veterinary precision medicine.

Read More
Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
Jill Lopez Jill Lopez

Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats

PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.

Read More

Your Questions, Answered

  • Vet Candy welcomes relevant industry news, press releases, and high-quality content that provides value to veterinary professionals. Submissions should focus on clinical insights, innovation in animal health, or meaningful industry developments.

    All submissions are reviewed by our editorial team to ensure they align with our content standards and audience interests. To inquire about opportunities, please contact our team through the website.

  • Vet Candy focuses on content that is educational, engaging, and relevant to veterinarians, vet techs, and veterinary students. This includes clinical updates, industry news, career insights, and expert perspectives that help professionals stay informed and grow in their careers.

  • Yes, Vet Candy offers opportunities for companies and organizations to share important updates, product news, and industry announcements through sponsored content, press features, and integrated campaigns—helping you reach a highly engaged veterinary audience.

  • You can reach us anytime via our contact page or email. We aim to respond quickly—usually within one business day.

  • Vet Candy is committed to providing content that is accurate, balanced, and relevant to veterinary professionals. Our editorial team works to maintain high journalistic standards by reviewing content for clarity, credibility, and educational value. We aim to present information in a way that reflects a range of perspectives within the veterinary industry.

  • We strive for accuracy in everything we publish, but if you notice an error or outdated information, we encourage you to reach out to our team. Vet Candy is committed to transparency and will review and update content as needed to ensure it remains accurate and reliable.

  • Yes, Vet Candy regularly reviews and updates content to maintain accuracy and relevance. When necessary, corrections or edits are made to ensure our content reflects the most current and reliable information available.